James Abbruzzese, MD

Professor of Medicine
D. C. I. Professor of Medical Oncology
Chief, Division of Medical Oncology
Member of the Duke Cancer Institute
Campus mail 440 Mudd Building, Box 3406, Durham, NC 27710
Email address james.abbruzzese@duke.edu

My research interests include the clinical study and treatment of pancreatic cancer.

In Their Words

Education and Training

  • Resident, Internal Medicine, Johns Hopkins University School of Medicine, 1979 - 1981
  • Intern, Internal Medicine, Johns Hopkins University School of Medicine, 1978 - 1979
  • M.D., The University of Chicago, 1978

Publications

Raijman, I., I. Siddique, P. Lynch, Y. Patt, M. Roh, S. Curley, J. Lee, P. Pisters, D. Evans, and J. Abbruzzese. “Comparison between metastatic vs primary biliary tract cancer in their response to the wallstent.” Gastrointestinal Endoscopy 45, no. 4 (January 1, 1997). https://doi.org/10.1016/S0016-5107(97)80482-8.

Full Text

Evans, D. B., J. E. Lee, P. W. Pisters, C. Charnsangavej, L. M. Ellis, P. J. Chiao, R. Lenzi, and J. L. Abbruzzese. “Advances in the diagnosis and treatment of adenocarcinoma of the pancreas.” Cancer Treat Res 90 (1997): 109–25. https://doi.org/10.1007/978-1-4615-6165-1_6.

PMID
9367080
Full Text

Abbruzzese, J. L., D. B. Evans, I. Raijman, L. Larry, T. King, S. D. Leach, and M. L. Frazier. “Detection of mutated c-Ki-ras in the bile of patients with pancreatic cancer.” Anticancer Research 17, no. 2 A (1997): 795–801.

Scholars@Duke

Mason, K. A., N. R. Hunter, M. Milas, J. L. Abbruzzese, and L. Milas. “Docetaxel enhances tumor radioresponse in vivo.” Clinical Cancer Research 3, no. 12 I (1997): 2431–38.

Scholars@Duke

Evans, D. B., C. A. Staley, J. E. Lee, P. W. T. Pisters, and J. L. Abbruzzese. “Adenocarcinoma of the pancreas: recent controversies, current management, and future therapies.” Gi Cancer 1, no. 3 (December 1, 1996): 149–61.

Scholars@Duke

Sinicrope, F. A., D. B. Evans, S. D. Leach, K. R. Cleary, C. J. Fenoglio, J. J. Lee, and J. L. Abbruzzese. “bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome.” Clin Cancer Res 2, no. 12 (December 1996): 2015–22.

PMID
9816161
Scholars@Duke

Beran, M., H. Kantarjian, S. O’Brien, C. Koller, M. al-Bitar, S. Arbuck, S. Pierce, et al. “Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.” Blood 88, no. 7 (October 1, 1996): 2473–79.

PMID
8839838
Scholars@Duke

Abbruzzese, J. L. “Phase I studies with the novel nucleoside analog gemcitabine.” Semin Oncol 23, no. 5 Suppl 10 (October 1996): 25–31.

PMID
8893878
Scholars@Duke

Abbruzzese, J. L., T. Madden, S. M. Sugarman, A. L. Ellis, S. Loughlin, K. R. Hess, R. A. Newman, L. A. Zwelling, and M. N. Raber. “Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.” Clin Cancer Res 2, no. 9 (September 1996): 1489–97.

PMID
9816325
Scholars@Duke

Rothenberg, M. L., J. L. Abbruzzese, M. Moore, R. K. Portenoy, J. M. Robertson, and H. J. Wanebo. “A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma.” Cancer 78, no. 3 Suppl (August 1, 1996): 627–32. https://doi.org/10.1002/(SICI)1097-0142(19960801)78:3<627::AID-CNCR43>3.0.CO;2-Y.

PMID
8681301
Full Text

Pages